Blood

Vol. 146, Issue Supplement 1 Issue Supplement 1 2025
8248
Articles

Articles in this Issue

Post-transplant cyclophosphamide (PTCy) versus other graft-versus-host disease prophylaxis strategies in reduced intensity allogeneic stem cell transplantation from related and matched unrelated donors in patients with acute myeloid leukemia and myelodysplastic syndromes: A study from the french society of bone marrow transplantation (SFGM-TC) registry

Tereza Coman, Stéphane Morisset, Raynier Devillier et al. Nov 03, 2025 pp. 2450-2450 10.1182/blood-2025-2450

Abstract Graft-versus-host disease (GVHD) remains a major cause of morbidity and mortality after allogeneic hematopoietic cell transplantati...

CD7 chimeric antigen receptor T cells for relapsed/refractory T-cell lymphomas: Single-arm, open-label, phase I study

Fan Yang, Rui Liu, Yuelu Guo et al. Nov 03, 2025 pp. 2368-2368 10.1182/blood-2025-2368

Abstract Background: The prognosis of refractory/relapsed T-cell lymphoma is extremely poor, especially for the patients who failed to allog...

Long-term transfusion-free duration and impact on transfusion-related burdens: Results from the ongoing ENERGIZE-T open-label extension study of mitapivat in transfusion-dependent alpha- or beta-thalassemia

Sujit Sheth, Jeremie Estepp, Gavrielle Price et al. Nov 03, 2025 pp. 4697-4697 10.1182/blood-2025-4697

Abstract Introduction: While regular transfusions and iron chelators have improved survival and outcomes in individuals with thalassemia, th...

Elucidating gene alterations driving hematopoietic dysfunction in PNH via patient-derived ips cell modeling and whole-genome sequencing

Jiyuan Liao, Yasushi Soda, Kiyoshi Yamaguchi et al. Nov 03, 2025 pp. 28-28 10.1182/blood-2025-28

Abstract Introduction Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, life-threatening hematologic disorder caused...

Unconventional mechanism of estrogen-induced thrombosis: The role of tissue factor and non-canonical pathways

Murat Yaman, Xinge Yu, Jacqueline Lee et al. Nov 03, 2025 pp. 1284-1284 10.1182/blood-2025-1284

Abstract Venous thromboembolism (VTE) is the third leading cause of cardiovascular mortality in the U.S., affecting ~900,000 individuals and...

Long-term outcomes, survival predictors and up-front treatment patterns in 568 elderly diffuse large b-cell lymphoma patients from LATAM: Is R-CHOP still the first choice for treating patients older than 60 years?

Rita De Vita, Cadiele Reichert, Hebert Culler et al. Nov 03, 2025 pp. 5437-5437 10.1182/blood-2025-5437

Abstract Introduction: Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma, occurring preferentially in...

Prognostic impact of molecular genetic and cytogenetic alterations in newly diagnosed acute myeloid leukemia treated with azacitidine and venetoclax: A real-world cohort study

Cristiano Machado De Freitas, Aarya Murali, Zahra Alhaj Issa et al. Nov 03, 2025 pp. 4776-4776 10.1182/blood-2025-4776

Abstract Introduction:Azacitidine and venetoclax (Aza-Ven) is the standard of care for older or unfit patients (pts) with newly diagnosed AM...

A randomized phase 2 trial of CPX-351 vs. CLAG-m (Cladribine, High-Dose Cytarabine, G-CSF, and Mitoxantrone) in medically less-fit adults with previously untreated acute myeloid leukemia (AML) or other high-grade myeloid neoplasms

Anna Halpern, Megan Othus, Mary-Elizabeth Percival et al. Nov 03, 2025 pp. 1663-1663 10.1182/blood-2025-1663

Abstract Background: While treatment options have significantly expanded for medically less-fit adults with newly diagnosed AML over the las...

A myeloid transcriptional signature stratifies outcomes in newly diagnosed ETP-ALL

Eitan Kugler, Ken Furudate, Farhad Ravandi et al. Nov 03, 2025 pp. 5151-5151 10.1182/blood-2025-5151

Abstract Background T-cell acute lymphoblastic leukemia (T-ALL) accounts for ~25% of adult ALL and is classified by immunophenotypic (IP) ma...

Azacitidine (AZA) and venetoclax (VEN) combination for the treatment of immune mediate inflammatory diseases (IMID) associated with myeloid neoplasms (MN)

Armelle Otiniano, Vincent Jachiet, Jérome Hadjadj et al. Nov 03, 2025 pp. 5630-5630 10.1182/blood-2025-5630

Abstract Background: IMID occurring in patients with MN, particularly studied in France by our MINHEMON group, are associated with substanti...

De novo secondary central nervous system lymphoma: A real-world cohort study over two decades

Jia Xin Chim, Shun Zi Liong, Lawrence Ng et al. Nov 03, 2025 pp. 8085-8085 10.1182/blood-2025-8085

Abstract Secondary central nervous system lymphoma (SCNSL) involves CNS spread of systemic lymphoma, occurring at diagnosis (de novo) or at...

Spanish real-life practice confirms zanubrutinib as a safe and effective option in relapsed or refractory marginal zone lymphoma: Results of a cohort of 118 patients on behalf of GELTAMO.

Ana Muntanola Prat, Fernando Martin-Moro, Xabier Gutiérrez et al. Nov 03, 2025 pp. 5350-5350 10.1182/blood-2025-5350

Abstract Introduction: There is no established standard of care for relapsed or refractory (R/R) marginal zone lymphoma...

Sickle cell disease in europe: A cross-border real-world data analysis from the radeep registry

Anna Collado Gimbert, Sara Reidel, Raffaella Colombatti et al. Nov 03, 2025 pp. 179-179 10.1182/blood-2025-179

Abstract Introduction Advances in understanding the pathophysiology and clinical heterogeneity of sickle cell disease (S...

Development and validation of a novel pathologically-based prognostic model for primary central nervous system lymphoma

Yupiao Feng, Xinting Hu, Yutang Li et al. Nov 03, 2025 pp. 5446-5446 10.1182/blood-2025-5446

Abstract Background: Although the IELSG and MSKCC prognostic scoring systems for PCNSL are widely used, their clinical applicability remains...

Valemetostat monotherapy in patients with relapsed or refractory B-cell lymphoma: Final results of the Phase 2 valym study from the lysa

Emmanuel Bachy, Fontanet Bijou, Bohrane Slama et al. Nov 03, 2025 pp. 1797-1797 10.1182/blood-2025-1797

Abstract Introduction. B-cell lymphomas comprise a broad spectrum of diseases, with clinical courses ranging from frequently relapsing indol...

Artificial intelligence-based diagnosis of myelodysplastic syndromes/neoplasms using bone marrow

Palak Dave, Ling Zhang, Joseph Pierce et al. Nov 03, 2025 pp. 5642-5642 10.1182/blood-2025-5642

Abstract Background: Accurate diagnosis of myelodysplastic syndromes (MDS) relies on hematopathologist evaluation of bone marrow (BM) specim...

Serum ferritin changes in iptacopan-treated patients with paroxysmal nocturnal hemoglobinuria

Antonio Risitano, Carlos de Castro, Camilla Frieri et al. Nov 03, 2025 pp. 4974-4974 10.1182/blood-2025-4974

Abstract Introduction: Patients with paroxysmal nocturnal hemoglobinuria (PNH) often develop iron deficiency (ID) due to chronic intravascul...

Tafasitamab-containing regimens in relapsed/refractory diffuse large B-cell lymphoma: A real-world retrospective case series

Jingyi Xie, Jinshan Gu, Rui Jia et al. Nov 03, 2025 pp. 7226-7226 10.1182/blood-2025-7226

Abstract Introduction: Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma (Br J Haematol 2024;205(6):2...

Immune reconstitution after venetoclax-based treatments in CLL

Tulsi Patel, Nirja Shah, Benjamin Heyman et al. Nov 03, 2025 pp. 7403-7403 10.1182/blood-2025-7403

Abstract Background: Chronic lymphocytic leukemia (CLL)-associated hypogammaglobulinemia is well-established. A degree of humoral immune rec...

IL-2 mutein-mediated improvement of CAR T function in Relapsed/Refractory diffuse B cell lymphoma

Allan Pavy, Cooper Sailer, Shannon McSain et al. Nov 03, 2025 pp. 5880-5880 10.1182/blood-2025-5880

Abstract Although chimeric antigen receptor (CAR)-T cell therapy has transformed the treatment landscape of B-cell malignancies, many patien...

Utilization and outcome disparities in autologous hematopoietic stem celltransplantation among patients with multiple myeloma in the United States

Emeka Agudile, Marina Khan, Zarmina Khan et al. Nov 03, 2025 pp. 2794-2794 10.1182/blood-2025-2794

Abstract Background: Hematopoietic cell transplantation (HCT) is a complex and cost-intensive, but life-saving procedure...

Real-world treatment and safety outcomes of patients with Mantle Cell Lymphoma in the United States

Yangyang Liu, Andrew Park, Reno Leeming et al. Nov 03, 2025 pp. 1795-1795 10.1182/blood-2025-1795

Abstract Background: Mantle cell lymphoma (MCL) is an aggressive and rare form of B-cell non-Hodgkin's (NHL) lymphoma and accounts for 5-10...

Efficacy of venetoclax in the treatment of relapsed/refractory light-chain amyloidosis

Xinyi Xiong, Ai Guan, Yi Xu et al. Nov 03, 2025 pp. 5745-5745 10.1182/blood-2025-5745

Abstract Background Venetoclax (Ven) has shown promising efficacy in light-chain (AL) amyloidosis, particularly among patients with t(11;14)...

Real-world application of AI in expediting paroxysmal nocturnal hemoglobinuria diagnosis

Robert Dewor, Michal J. Dabrowski, Lukasz Wiecek et al. Nov 03, 2025 pp. 1415-1415 10.1182/blood-2025-1415

Abstract Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, chronic, potentially life-threatening hematological disorder that is associate...

Inflammatory Waldenström macroglobulinemia is associated with monocyte dysregulation and IL-1β production

Pierre-Edouard Debureaux, Harel Stephanie, Clémentine Moulin et al. Nov 03, 2025 pp. 1777-1777 10.1182/blood-2025-1777

Abstract Background Waldenström macroglobulinemia (WM) is a rare, indolent B-cell neoplasm characterized by bone marrow...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page